Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Carcinoma of the esophagus: Is there a role for surgery? The case against surgery.

The American journal of digestive diseases

Moertel CG.
PMID: 685942
Am J Dig Dis. 1978 Aug;23(8):735-6. doi: 10.1007/BF01072363.

No abstract available.

Cite
Moertel CG. Carcinoma of the esophagus: Is there a role for surgery? The case against surgery. Am J Dig Dis. 1978;23(8):735-6doi: 10.1007/BF01072363.
Moertel, C. G. (1978). Carcinoma of the esophagus: Is there a role for surgery? The case against surgery. The American journal of digestive diseases, 23(8), 735-6. https://doi.org/10.1007/BF01072363
Moertel, C G. "Carcinoma of the esophagus: Is there a role for surgery? The case against surgery." The American journal of digestive diseases vol. 23,8 (1978): 735-6. doi: https://doi.org/10.1007/BF01072363
Moertel CG. Carcinoma of the esophagus: Is there a role for surgery? The case against surgery. Am J Dig Dis. 1978 Aug;23(8):735-6. doi: 10.1007/BF01072363. PMID: 685942.
Copy Download .nbib Format: NLM
Multiple primary malignant neoplasms. II. Tumors of different tissues or organs.

Cancer

MOERTEL CG, DOCKERTY MB, BAGGENSTOSS AH.
PMID: 13771653
Cancer. 1961 Mar-Apr;14:231-7. doi: 10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2.

No abstract available.

Cite
MOERTEL CG, DOCKERTY MB, BAGGENSTOSS AH. Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer. 1961;14:231-7doi: 10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2.
MOERTEL, C. G., DOCKERTY, M. B., & BAGGENSTOSS, A. H. (1961). Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer, 14231-7. https://doi.org/10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2
MOERTEL, C G, et al. "Multiple primary malignant neoplasms. II. Tumors of different tissues or organs." Cancer vol. 14 (1961): 231-7. doi: https://doi.org/10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2
MOERTEL CG, DOCKERTY MB, BAGGENSTOSS AH. Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer. 1961 Mar-Apr;14:231-7. doi: 10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2. PMID: 13771653.
Copy Download .nbib Format: NLM
Synthesis and structures of Pb3O2(CH3COO)2·0.5H2O and Pb2O(HCOO)2: two corrosion products revisited.

Inorganic chemistry

Mauck CM, van den Heuvel TW, Hull MM, Zeller M, Oertel CM.
PMID: 20961144
Inorg Chem. 2010 Nov 15;49(22):10736-43. doi: 10.1021/ic101904j. Epub 2010 Oct 20.

Reactions of carboxylic acids with lead play an important role in the atmospheric corrosion of lead and lead-tin alloys. This is of particular concern for the preservation of lead-based cultural objects, including historic lead-tin alloy organ pipes. Two initial...

Cite
Mauck CM, van den Heuvel TW, Hull MM, et al. Synthesis and structures of Pb3O2(CH3COO)2·0.5H2O and Pb2O(HCOO)2: two corrosion products revisited. Inorg Chem. 2010;49(22):10736-43doi: 10.1021/ic101904j.
Mauck, C. M., van den Heuvel, T. W., Hull, M. M., Zeller, M., & Oertel, C. M. (2010). Synthesis and structures of Pb3O2(CH3COO)2·0.5H2O and Pb2O(HCOO)2: two corrosion products revisited. Inorganic chemistry, 49(22), 10736-43. https://doi.org/10.1021/ic101904j
Mauck, Catherine M, et al. "Synthesis and structures of Pb3O2(CH3COO)2·0.5H2O and Pb2O(HCOO)2: two corrosion products revisited." Inorganic chemistry vol. 49,22 (2010): 10736-43. doi: https://doi.org/10.1021/ic101904j
Mauck CM, van den Heuvel TW, Hull MM, Zeller M, Oertel CM. Synthesis and structures of Pb3O2(CH3COO)2·0.5H2O and Pb2O(HCOO)2: two corrosion products revisited. Inorg Chem. 2010 Nov 15;49(22):10736-43. doi: 10.1021/ic101904j. Epub 2010 Oct 20. PMID: 20961144.
Copy Download .nbib Format: NLM
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Current oncology reports

Galvin R, Watson AL, Largaespada DA, Ratner N, Osum S, Moertel CL.
PMID: 33721151
Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y.

PURPOSE OF REVIEW: Patients with neurofibromatosis type 1 (NF1) are at increased risk for benign and malignant neoplasms. Recently, targeted therapy with the MEK inhibitor class has helped address these needs. We highlight recent successes with selumetinib while acknowledging...

Cite
Galvin R, Watson AL, Largaespada DA, et al. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Curr Oncol Rep. 2021;23(4):45doi: 10.1007/s11912-021-01032-y.
Galvin, R., Watson, A. L., Largaespada, D. A., Ratner, N., Osum, S., & Moertel, C. L. (2021). Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current oncology reports, 23(4), 45. https://doi.org/10.1007/s11912-021-01032-y
Galvin, Robert, et al. "Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib." Current oncology reports vol. 23,4 (2021): 45. doi: https://doi.org/10.1007/s11912-021-01032-y
Galvin R, Watson AL, Largaespada DA, Ratner N, Osum S, Moertel CL. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y. PMID: 33721151.
Copy Download .nbib Format: NLM
Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea.

Child neurology open

Evans E, Nascene D, Sommer K, Moertel C.
PMID: 31763344
Child Neurol Open. 2019 Aug 06;6:2329048X19866617. doi: 10.1177/2329048X19866617. eCollection 2019.

The authors present 2 cases of cross-innervation in patients with neurofibromatosis type 2. In the first case, an iodine test was performed to demonstrate Frey syndrome in a 28-year-old female with neurofibromatosis type 2 who developed symptoms at age...

Cite
Evans E, Nascene D, Sommer K, et al. Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea. Child Neurol Open. 2019;6:2329048X19866617doi: 10.1177/2329048X19866617.
Evans, E., Nascene, D., Sommer, K., & Moertel, C. (2019). Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea. Child neurology open, 62329048X19866617. https://doi.org/10.1177/2329048X19866617
Evans, Erica, et al. "Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea." Child neurology open vol. 6 (2019): 2329048X19866617. doi: https://doi.org/10.1177/2329048X19866617
Evans E, Nascene D, Sommer K, Moertel C. Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey Syndrome and Unilateral Epiphora With Rhinorrhea. Child Neurol Open. 2019 Aug 06;6:2329048X19866617. doi: 10.1177/2329048X19866617. eCollection 2019. PMID: 31763344; PMCID: PMC6852346.
Copy Download .nbib Format: NLM
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR.
PMID: 33829411
Neurotherapeutics. 2021 Jul;18(3):1980-1994. doi: 10.1007/s13311-021-01038-1. Epub 2021 Apr 07.

Numerous therapies aimed at driving an effective anti-glioma response have been employed over the last decade; nevertheless, survival outcomes for patients remain dismal. This may be due to the expression of immune-checkpoint ligands such as PD-L1 by glioblastoma (GBM)...

Cite
Ampudia-Mesias E, Puerta-Martinez F, Bridges M, et al. CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics. 2021;18(3):1980-1994doi: 10.1007/s13311-021-01038-1.
Ampudia-Mesias, E., Puerta-Martinez, F., Bridges, M., Zellmer, D., Janeiro, A., Strokes, M., Sham, Y. Y., Taher, A., Castro, M. G., Moertel, C. L., Pluhar, G. E., & Olin, M. R. (2021). CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1980-1994. https://doi.org/10.1007/s13311-021-01038-1
Ampudia-Mesias, Elisabet, et al. "CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 18,3 (2021): 1980-1994. doi: https://doi.org/10.1007/s13311-021-01038-1
Ampudia-Mesias E, Puerta-Martinez F, Bridges M, Zellmer D, Janeiro A, Strokes M, Sham YY, Taher A, Castro MG, Moertel CL, Pluhar GE, Olin MR. CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. Neurotherapeutics. 2021 Jul;18(3):1980-1994. doi: 10.1007/s13311-021-01038-1. Epub 2021 Apr 07. PMID: 33829411; PMCID: PMC8609078.
Copy Download .nbib Format: NLM
Maternal Contraceptive Use and Central Nervous System Tumors in Offspring.

JAMA

Spector LG, Moertel CL, Su HI.
PMID: 34982137
JAMA. 2022 Jan 04;327(1):39-40. doi: 10.1001/jama.2021.21809.

No abstract available.

Cite
Spector LG, Moertel CL, Su HI. Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA. 2022;327(1):39-40doi: 10.1001/jama.2021.21809.
Spector, L. G., Moertel, C. L., & Su, H. I. (2022). Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA, 327(1), 39-40. https://doi.org/10.1001/jama.2021.21809
Spector, Logan G, et al. "Maternal Contraceptive Use and Central Nervous System Tumors in Offspring." JAMA vol. 327,1 (2022): 39-40. doi: https://doi.org/10.1001/jama.2021.21809
Spector LG, Moertel CL, Su HI. Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA. 2022 Jan 04;327(1):39-40. doi: 10.1001/jama.2021.21809. PMID: 34982137.
Copy Download .nbib Format: NLM
Maternal Contraceptive Use and Central Nervous System Tumors in Offspring.

JAMA

Spector LG, Moertel CL, Su HI.
PMID: 34982137
JAMA. 2022 Jan 04;327(1):39-40. doi: 10.1001/jama.2021.21809.

No abstract available.

Cite
Spector LG, Moertel CL, Su HI. Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA. 2022;327(1):39-40doi: 10.1001/jama.2021.21809.
Spector, L. G., Moertel, C. L., & Su, H. I. (2022). Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA, 327(1), 39-40. https://doi.org/10.1001/jama.2021.21809
Spector, Logan G, et al. "Maternal Contraceptive Use and Central Nervous System Tumors in Offspring." JAMA vol. 327,1 (2022): 39-40. doi: https://doi.org/10.1001/jama.2021.21809
Spector LG, Moertel CL, Su HI. Maternal Contraceptive Use and Central Nervous System Tumors in Offspring. JAMA. 2022 Jan 04;327(1):39-40. doi: 10.1001/jama.2021.21809. PMID: 34982137.
Copy Download .nbib Format: NLM
Engagement in Human-Agent Interaction: An Overview.

Frontiers in robotics and AI

Oertel C, Castellano G, Chetouani M, Nasir J, Obaid M, Pelachaud C, Peters C.
PMID: 33501259
Front Robot AI. 2020 Aug 04;7:92. doi: 10.3389/frobt.2020.00092. eCollection 2020.

Engagement is a concept of the utmost importance in human-computer interaction, not only for informing the design and implementation of interfaces, but also for enabling more sophisticated interfaces capable of adapting to users. While the notion of engagement is...

Cite
Oertel C, Castellano G, Chetouani M, et al. Engagement in Human-Agent Interaction: An Overview. Front Robot AI. 2020;7:92doi: 10.3389/frobt.2020.00092.
Oertel, C., Castellano, G., Chetouani, M., Nasir, J., Obaid, M., Pelachaud, C., & Peters, C. (2020). Engagement in Human-Agent Interaction: An Overview. Frontiers in robotics and AI, 792. https://doi.org/10.3389/frobt.2020.00092
Oertel, Catharine, et al. "Engagement in Human-Agent Interaction: An Overview." Frontiers in robotics and AI vol. 7 (2020): 92. doi: https://doi.org/10.3389/frobt.2020.00092
Oertel C, Castellano G, Chetouani M, Nasir J, Obaid M, Pelachaud C, Peters C. Engagement in Human-Agent Interaction: An Overview. Front Robot AI. 2020 Aug 04;7:92. doi: 10.3389/frobt.2020.00092. eCollection 2020. PMID: 33501259; PMCID: PMC7806067.
Copy Download .nbib Format: NLM
p53 protein expression in conjunctival squamous cell carcinomas of domestic animals.

Veterinary ophthalmology

Sironi G, Riccaboni P, Mertel L, Cammarata G, Brooks DE.
PMID: 11397270
Vet Ophthalmol. 1999;2(4):227-231. doi: 10.1046/j.1463-5224.1999.00086.x.

The expression of p53 protein was investigated in eight formalin-fixed, paraffin-embedded conjunctival squamous cell carcinomas of five horses and one cow, dog and cat each by an immunohistochemical procedure in order to evaluate protein overexpression. Anti-human p53 protein mouse...

Cite
Sironi G, Riccaboni P, Mertel L, et al. p53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Vet Ophthalmol. 1999;2(4):227-231doi: 10.1046/j.1463-5224.1999.00086.x.
Sironi, G., Riccaboni, P., Mertel, L., Cammarata, G., & Brooks, D. E. (1999). p53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Veterinary ophthalmology, 2(4), 227-231. https://doi.org/10.1046/j.1463-5224.1999.00086.x
Sironi, Giuseppe, et al. "p53 protein expression in conjunctival squamous cell carcinomas of domestic animals." Veterinary ophthalmology vol. 2,4 (1999): 227-231. doi: https://doi.org/10.1046/j.1463-5224.1999.00086.x
Sironi G, Riccaboni P, Mertel L, Cammarata G, Brooks DE. p53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Vet Ophthalmol. 1999;2(4):227-231. doi: 10.1046/j.1463-5224.1999.00086.x. PMID: 11397270.
Copy Download .nbib Format: NLM
The coexistence of primary lung cancer and other primary malignant neoplasms.

Diseases of the chest

MOERTEL CG, ANDERSEN HA, BAGGENSTOSS AH.
PMID: 13639792
Dis Chest. 1959 Apr;35(4):343-7. doi: 10.1378/chest.35.4.343.

No abstract available.

Cite
MOERTEL CG, ANDERSEN HA, BAGGENSTOSS AH. The coexistence of primary lung cancer and other primary malignant neoplasms. Dis Chest. 1959;35(4):343-7doi: 10.1378/chest.35.4.343.
MOERTEL, C. G., ANDERSEN, H. A., & BAGGENSTOSS, A. H. (1959). The coexistence of primary lung cancer and other primary malignant neoplasms. Diseases of the chest, 35(4), 343-7. https://doi.org/10.1378/chest.35.4.343
MOERTEL, C G, et al. "The coexistence of primary lung cancer and other primary malignant neoplasms." Diseases of the chest vol. 35,4 (1959): 343-7. doi: https://doi.org/10.1378/chest.35.4.343
MOERTEL CG, ANDERSEN HA, BAGGENSTOSS AH. The coexistence of primary lung cancer and other primary malignant neoplasms. Dis Chest. 1959 Apr;35(4):343-7. doi: 10.1378/chest.35.4.343. PMID: 13639792.
Copy Download .nbib Format: NLM
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.

Journal for immunotherapy of cancer

Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C.
PMID: 24829761
J Immunother Cancer. 2014 Feb 18;2:4. doi: 10.1186/2051-1426-2-4. eCollection 2014.

BACKGROUND: We tested the hypothesis that a novel vaccine developed from autologous dendritic cells (DC) loaded with cells from a unique allogeneic brain tumor cell line (GBM6-AD) would be well-tolerated and would generate an immune response.METHOD: Patients with recurrent...

Cite
Olin MR, Low W, McKenna DH, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer. 2014;2:4doi: 10.1186/2051-1426-2-4.
Olin, M. R., Low, W., McKenna, D. H., Haines, S. J., Dahlheimer, T., Nascene, D., Gustafson, M. P., Dietz, A. B., Clark, H. B., Chen, W., Blazar, B., Ohlfest, J. R., & Moertel, C. (2014). Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. Journal for immunotherapy of cancer, 24. https://doi.org/10.1186/2051-1426-2-4
Olin, Michael R, et al. "Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response." Journal for immunotherapy of cancer vol. 2 (2014): 4. doi: https://doi.org/10.1186/2051-1426-2-4
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer. 2014 Feb 18;2:4. doi: 10.1186/2051-1426-2-4. eCollection 2014. PMID: 24829761; PMCID: PMC4019901.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries